Mr. Hugh Rogers reports

BIONXT SOLUTIONS ANNOUNCES CLOSING OF FIRST TRANCHE OF CONVERTIBLE DEBENTURE UNIT PRIVATE PLACEMENT

Bionxt Solutions Inc. has closed the first tranche of its previously announced non-brokered private placement of convertible debenture units for gross proceeds of $1.6-million. Each debenture unit consists of: (i) 50 cents principal amount of 8.0 per cent unsecured convertible debentures; and (ii) one common share purchase warrant. The company anticipates closing one or more tranches of the offering in the coming weeks.

The debentures bear interest from their issue date at 8.0 per cent per annum on an accrual basis, calculated and payable at maturity, which is two years following the date of issuance. The debentures are convertible at the option of the holder into common shares of the company at any time prior to the maturity date at a conversion price of 50 cents per common share. The interest payable on the principal amount of the debenture may be paid through the issuance of common shares at the conversion price at the election of the company.

Each warrant is exercisable to acquire one common share at an exercise price of 60 cents per warrant share until Feb. 28, 2027.

In connection with the offering, the company paid a cash fee of $128,000 and issued 256,000 finder's warrants to Canaccord Genuity Corp. Each finder's warrant entitles the holder thereof to purchase one common share at an exercise price of 50 cents until Feb. 28, 2027.

The debentures and the warrants comprising each debenture unit, the finder's warrants, and any common shares issuable upon conversion or exercise thereof, are subject to a statutory four-month-and-one-day hold period until June 29, 2025.

The company intends to use the net proceeds from the offering for product development and commercialization, intellectual property filings, debt repayment, and general working capital.

About Bionxt Solutions Inc.

Bionxt Solutions is a bioscience innovator focused on next-generation drug delivery technologies, diagnostic screening systems and active pharmaceutical ingredient development. The company's proprietary platforms, sublingual (thin film), transdermal (skin patch) and oral (enteric-coated tablets), target key therapeutic areas, including autoimmune diseases, neurological disorders and longevity.

With research and development operations in North America and Europe, Bionxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. Bionxt is committed to improving health care by delivering precise, patient-centric solutions that enhance treatment outcomes worldwide.

Bionxt is listed on the Canadian Securities Exchange under the symbol BNXT and on the OTC (over-the-counter) markets under the symbol BNXTF, and trades in Germany under WKN: A3D1K3.

We seek Safe Harbor.